References
Yang LPH, Keam SJ. Sugammadex: a review of its use in anaesthetic practice. Drugs 2009; 69(7): 919–42
Blobner M, Eriksson L, Scholz J, et al. Sugammadex (2.0 mg/kg) significantly faster reverses shallow rocuronium-induced neuro-muscular blockade compared with neostigmine (50 (μg/kg) [abstract no. 9AP7-10]. Eur J Anaesthesiol 2007 Jun; 24: 125. Plus poster presented at the 2007 Congress of the European Society of Anaethesiology; 2007 Jun 9–12; Munich
Jones RK, Caldwell JE, Brull SJ, et al. Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology 2008 Nov; 109(5): 816–24
Flockton EA, Mastronardi P, Hunter JM, et al. Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine. Br J Anaesth 2008 May; 100(5): 622–30
Lee C, Jahr JS, Candiotti KA, et al. Reversal of profound neuromuscular block by sugammadex administered 3 minutes after rocuronium: a comparison with spontaneous recovery from succinylcholine. Anesthesiology 2009 May; 110(5): 1020–5
Organon USA. FDA Anesthetic and Life Support Advisory Committee Meeting: briefing document (background package) for sugammadex sodium injection [online]. Available from URL: http://www.fda.gov/.pdf [Accessed 2009 Sep 14]
McDonagh DL, Benedict PE, Kovac AL, et al. Efficacy and safety of sugammadex for reversal of rocuronium-induced blockade in elderly patients [abstract A1583]. Anesthesiology 2007; 107 Suppl.
Plaud B, Meretoja O, Hofmockel R, et al. Reversal of rocuronium-induced neuromuscular blockade with sugammadex in pediatric and adult surgical patients. Anesthesiology 2009 Feb; 110(2): 284–94
Staals LM, Snoeck MMJ, Driessen JJ, et al. Multicentre, parallel-group, comparative trial evaluating the efficacy and safety of sugammadex in patients with end-stage renal failure or normal renal function. Br J Anaesth 2008 Oct; 101(4): 492–7
Dahl V, Pendeville PE, Hollmann MW, et al. Safety and efficacy of sugammadex for the reversal of rocuronium-induced neuromuscular blockade in cardiac patients undergoing noncardiac surgery. Eur J Anaesthesiol 2009 Oct; 26(10): 874–84
Amao R, Zornow MH, McTaggart Cowan R, et al. Sugammadex safely reverses rocuronium-induced blockade in patients with pulmonary disease [abstract A1582]. Anesthesiology 2007; 107 Suppl.
Khuenl-Brady KS, Wattwil M, Vanacker BF, et al. Sugammadex provides faster reversal of vecuronium-induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial. Anesth Analg. Epub 2009 Aug 27
Lemmens HJM, El-Orbany MI, Berry J, et al. Sugammadex reverses profound vecuronium blockade more rapidly than neostigmine [abstract A1578]. Anesthesiology 2007; 107 Suppl.
European Medicines Agency. Bridion (sugammadex) 100 mg/mL: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu [Accessed 2009 Jul 31]
Rights and permissions
About this article
Cite this article
Sugammadex: a guide to its use in anaesthetic practice. Drugs Ther. Perspect 25, 5–8 (2009). https://doi.org/10.2165/0042310-200925110-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/0042310-200925110-00002